Ironwood Pharmaceuticals
301 Binney Street
Cambridge
Massachusetts
02142
United States
Tel: 617-621-7722
Fax: 617-494-0480
Website: http://www.ironwoodpharma.com/
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma.
416 articles about Ironwood Pharmaceuticals
-
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
8/4/2022
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results.
-
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
7/21/2022
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 4, 2022.
-
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
5/25/2022
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week ® (DDW) 2022.
-
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
5/9/2022
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week ® 2022.
-
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
5/5/2022
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its first quarter 2022 results and recent business performance.
-
Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call
4/21/2022
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 5, 2022.
-
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences in March 2022
3/2/2022
Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, announced that management will be presenting at the following investor conferences:
-
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021
2/17/2022
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2021 results.
-
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call
2/3/2022
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 17, 2022.
-
Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance
1/10/2022
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided updated financial guidance for full year 2021 and announced financial guidance for full year 2022.
-
Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference.
-
BioSpace Movers & Shakers, Dec. 3
12/3/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
12/1/2021
Ironwood Pharmaceuticals, Inc. today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer.
-
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
11/4/2021
Ironwood Pharmaceuticals, Inc. today reported financial results for third quarter 2021.
-
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
11/4/2021
Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, announced that it is expanding its pipeline by entering into a collaboration and license option agreement with COUR Pharmaceutical Development Company, Inc., a biotechnology company developing novel immune-modifying nanoparticles to treat autoimmune diseases.
-
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021
10/25/2021
Ironwood Pharmaceuticals, Inc. will present new findings at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting and Postgraduate Course from a survey highlighting prevalence and impact of abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C).
-
Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call
10/21/2021
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 4, 2021.
-
Ironwood Pharmaceuticals to Participate in Upcoming September 2021 Investor Conferences
9/2/2021
Ironwood Pharmaceuticals, Inc. will participate in fireside chats at two upcoming virtual investor conferences in September.
-
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label
8/26/2021
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS ® (linaclotide) Label based on clinical safety data that has been generated thus far in pediatric studies.
-
Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
8/5/2021
Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, reported financial results for second quarter 2021 and raised full year 2021 financial guidance.